News

Findings from the SHAWL study found that sexual dysfunction rates are high among women with lung cancer.

The results of the phase 3 MASTERKEY-265 trial show that there is still an unmet need for patients who are refractory to pembrolizumab and anti–PD-1 inhibitors.

The nurse care pathway outlines best practices for monitoring, and responding to, pneumocystis jirovecii pneumonia risk in patients with multiple myeloma receiving novel, high-risk therapies.

Phase 2 findings from the CADENZA trial suggest that pivekimab sunirine may be effective against blastic plasmacytoid dendritic cell neoplasm, a rare and aggressive form of hematologic cancer.

Compared with gefitinib monotherapy, a combo regimen of gefitinib plus chemotherapy generated superior time to second progression in untreated non–small cell lung cancer.

At a median follow-up of 22.9 months, patients with platinum-refractory metastatic urothelial carcinoma achieved a median overall survival of 14.6 months with EphB4-human serum albumin plus pembrolizumab.

Adding plinabulin to prophylactic pegfilgrastim and antibiotics may help prevent nonengraftment–related febrile neutropenia.

The FDA has approved durvalumab for patients with advanced or metastatic biliary tract cancers. The immunotherapy comes with warnings for immune-related adverse events and infusion reactions.

Findings of a retrospective analysis of patients with multiple myeloma showed that the median duration of treatment with daratumumab was 16.6 months.

Best management strategies for vancomycin infusion reactions may include premedication, infusion-rate adjustment, and, in some cases, alternative antibiotic therapy.

In this episode of "The Vitals," Sarah Donahue, MPH, NP, AOCNP; Jamie Carroll, APRN, CNP, MSN; Theresa Wicklin Gillespie, PhD, MA, RN, FAAN; and Elizabeth Prechtel-Dunphy, DNP, RN, ANP-BC, AOCN, exchange clinical pearls for treating patients receiving antibody-drug conjugates.

There is no one-size-fits-all approach to establishing patient-reported outcome measures, according to Hayley Beer, RN.

Sotorasib is often associated with a high rate of hepatotoxic events, most of which are from elevated liver enzymes. However, a lead-in dosing strategy may help address this adverse event and improve patient tolerability.

Each month, we take a look back at the most popular Oncology Nursing News® stories. Here are the top 5 stories from August 2022.

A post hoc analysis from the phase 2 DREAMM-2 trial highlighted the ocular toxicity risks that belantamab mafodotin poses for patients with multiple myeloma.

Younger women who underwent endoscopies had a reduced risk of colorectal cancer incidence, according to findings of a prospective cohort study.

An observational study found no association between single-agent vaginal estrogen therapy or menopausal hormone therapy and increased risk of recurrence or mortality in patients with breast cancer.

Starting patients with unresectable or metastatic renal cell carcinoma on a reduced dose of VEGF tyrosine kinase inhibitor (TKI) therapy did not compromise survival outcomes.

A combination of niraparib plus ipilimumab were associated with a 6-month PFS rate of 59.6%, whereas a combination of nivolumab plus the PARP inhibitor yielded a rate of 20.6%.

Investigators at Dana-Farber Cancer Institute are developing a virtual frailty assessment, which combines both patient-reported outcomes and standardized performance measures.

Pemigatinib has received FDA approval for relapsed or refractory myeloid/lymphoid neoplasms and FGFR1 rearrangement. Patients receiving pemigatinib will require monitoring for ocular toxicities and high phosphate levels.

Daniel J. Verina, DNP, RN, MSN, ACNP-BC, highlights optimal adverse event management with CD38- and SLAM-F7-directed monoclonal antibodies, XPO-1 inhibitors, and CAR T-cell therapies.

Ibrutinib is now an FDA-approved treatment for patients aged 1 year or older who have chronic graft-versus-host-disease. Prescription warnings include bleeding and cardiac problems, infections, high blood pressure, a decrease in blood cell count, and tumor lysis syndrome.

Through patient education tactics, oncology nurses can help patients with multiple myeloma mitigate the oral and dermatologic toxicities associated with talquetamab.

When combined with neoadjuvant chemotherapy, galunisertib induced complete response rates surpassing rates achieved with standard-of-care therapy in locally advanced rectal cancer.

In 17 years, the mortality rate for Black women with breast cancer has not changed.

Rucaparib may be a viable maintenance therapy option for patients with DNA repair–deficient positive, metastatic urothelial cancer who are unlikely to benefit from avelumab immunotherapy.

Paula Anastasia, RN, MN, AOCN, underscores the value of genetic testing in personalizing treatment decisions in ovarian maintenance therapy.

Advanced practice providers play a critical role in increasing palliative care referrals.

A study presented at the 2022 World Conference on Lung Cancer explored the experiences of patients who received checkpoint inhibition therapy for non–small cell lung cancer.